Alector Competitors

Alector (NASDAQ:ALEC) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of -0.99, indicating that its stock price is 199% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Vir Biotechnology, as reported by MarketBeat.com.

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Vir Biotechnology has a consensus target price of $63.8571, indicating a potential upside of 60.97%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Vir Biotechnology.

Profitability

This table compares Alector and Vir Biotechnology's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alector and Vir Biotechnology's top-line revenue, earnings per share and valuation.

Alector has higher revenue and earnings than Vir Biotechnology. Alector is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 54.5% of Vir Biotechnology shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 37.2% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alector beats Vir Biotechnology on 10 of the 14 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Kodiak Sciences, as reported by MarketBeat.com.

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Kodiak Sciences has a consensus target price of $129.1818, indicating a potential upside of 15.68%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Kodiak Sciences.

Profitability

This table compares Alector and Kodiak Sciences' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alector and Kodiak Sciences' top-line revenue, earnings per share and valuation.

Kodiak Sciences has lower revenue, but higher earnings than Alector. Kodiak Sciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 82.3% of Kodiak Sciences shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 39.3% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Kodiak Sciences beats Alector on 8 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional & Insider Ownership

61.5% of Alector shares are owned by institutional investors. Comparatively, 94.6% of Iovance Biotherapeutics shares are owned by institutional investors. 13.9% of Alector shares are owned by company insiders. Comparatively, 9.9% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Alector has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Alector and Iovance Biotherapeutics, as reported by MarketBeat.com.

Alector currently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Iovance Biotherapeutics has a consensus target price of $50.10, indicating a potential upside of 57.70%. Given Alector's stronger consensus rating and higher probable upside, equities analysts clearly believe Alector is more favorable than Iovance Biotherapeutics.

Profitability

This table compares Alector and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Alector and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

Alector has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Iovance Biotherapeutics on 8 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 2.7% of China Biologic Products shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Alector and China Biologic Products, as reported by MarketBeat.

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Given Alector's higher probable upside, equities research analysts plainly believe Alector is more favorable than China Biologic Products.

Profitability

This table compares Alector and China Biologic Products' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alector and China Biologic Products' top-line revenue, earnings per share and valuation.

China Biologic Products has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Summary

China Biologic Products beats Alector on 7 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Alector and Allogene Therapeutics, as reported by MarketBeat.

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Allogene Therapeutics has a consensus target price of $52.0833, indicating a potential upside of 60.60%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Allogene Therapeutics.

Profitability

This table compares Alector and Allogene Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alector and Allogene Therapeutics' top-line revenue, earnings per share and valuation.

Alector has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Allogene Therapeutics on 7 of the 13 factors compared between the two stocks.

Alector (NASDAQ:ALEC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Institutional and Insider Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Alector and Beam Therapeutics, as reported by MarketBeat.

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 107.18%. Beam Therapeutics has a consensus target price of $96.00, indicating a potential upside of 30.63%. Given Alector's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alector is more favorable than Beam Therapeutics.

Profitability

This table compares Alector and Beam Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alector and Beam Therapeutics' top-line revenue, earnings per share and valuation.

Beam Therapeutics has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Alector beats Beam Therapeutics on 10 of the 13 factors compared between the two stocks.